In addition, the study showed that the treatment with nintedanib of cultured M2 macrophages significantly reduced the release of the active form of TGFβ1 growth factor, that is overexpressed in SSc patients with ILD and potentially involved in the development of lung fibrosis. The gene discussed is TGFB1; the disease is pulmonary fibrosis.